GD2抗体达妥昔单抗β治疗神经母细胞瘤的临床应用专家共识（2021年版）
Expert consensus on GD2 antibody dinutuximab-β in the treatment of neuroblastoma
GD2单抗治疗神经母细胞瘤临床应用协作组 . GD2抗体达妥昔单抗β治疗神经母细胞瘤的临床应用专家共识（2021年版）[J]. 临床儿科杂志, 2022 , 40(1) : 14 -20 . DOI: 10.12372/jcp.2022.21e1685
| [1] | Tsubota S, Kadomatsu K. Origin and initiation mechanisms of neuroblastoma[J]. Cell Tissue Res, 2018, 372(2): 211-221. |
| [2] | Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma[J]. Lancet, 2007, 369: 2106-2120. |
| [3] | Brodeur GM, Marris JM. Neuroblastoma[M]//Pizzo PA, Poplack BG. Principles and practice of pediatric oncology, 5th ed. Philadelphia: Lippincott Williams &Wilkins; 2006: 933-970. |
| [4] | Gurney JG, Ross JA, Wall DA, et al. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992 [J]. J Pediatr Hematol Oncol, 1997, 19: 428. |
| [5] | Uemura S, Ishida T, Thwin KKM, et al. Dynamics of minimal residual disease in neuroblastoma patients[J]. Front Oncol, 2019, 9: 455. |
| [6] | 鲍萍萍, 李凯, 吴春晓, 等. 2002-2010年上海市户籍儿童恶性实体肿瘤发病特征和变化趋势分析[J]. 中华儿科杂志, 2013, 51(4): 288-294. |
| [7] | Liang WH, Federico SM, London WB, et al. Tailoring therapy for children with neuroblastoma on the basis of risk group classification: past, present, and future[J]. JCO Clin Cancer Inform, 2020, 4: 895-905. |
| [8] | Tas ML, Reedijk AMJ, Karim-Kos HE, et al. Neuro-blastoma between 1990 and 2014 in the Netherlands: increased incidence and improved survival of high-risk neuroblastoma[J]. Eur J Cancer, 2020, 124: 47-55. |
| [9] | Pastor ER, Mousa SA. Current management of neuro-blastoma and future direction[J]. Crit Rev Oncol Hematol, 2019, 138: 38-43. |
| [10] | Gains J, Mandeville H, Cork N, et al. Ten challenges in the management of neuroblastoma[J]. Future Oncol, 2012, 8(7): 839-58. |
| [11] | Shohet J, Foster J. Neuroblastoma[J]. BMJ, 2017, 357: j1863. |
| [12] | Zage PE. Novel therapies for relapsed and refractory neuroblastoma[J]. Children (Basel), 2018, 5(11): 148. |
| [13] | Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma[J]. Cancer Invest, 2007, 25(1): 67-77. |
| [14] | Kholodenko IV, Kalinovsky DV, Doronin II, et al. Neuroblastoma origin and therapeutic targets for immune therapy[J]. J Immunol Res, 2018, 2018: 7394268. |
| [15] | Voeller J, Sondel PM. Advances in anti-GD2 immuno therapy for treatment of high-risk neuroblastoma[J]. J Pediatr Hematol Oncol, 2019, 41(3): 163-169. |
| [16] | Mueller BM, Romerdahl CA, Gillies SD, et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody[J]. J Immunol, 1990, 144(4): 1382-1386. |
| [17] | Eusa Pharma UK. Legal Category[EB/OL]. [2021-12-07]. https://www.medicines.org.uk/emc/product/9441/smpc. |
| [18] | Siebert N, Eger C, Seidel D, et al. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2[J]. MAbs, 2016, 8(3): 604-616. |
| [19] | European Medicines Agency. Assessment report - Dinutuximab beta Apeiron[EB/OL]. https://www.ema.europa.eu/en/documents/assessment-report/dinutuximab-beta-apeiron-epar-public-assessment-report_en.pdf. |
| [20] | Ladenstein R, Potschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(12): 1617-1629. |
| [21] | Ladenstein R, Potschger U, Valteau-Couanet D, et al. Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1)[J]. Cancers (Basel), 2020, 12(2): 309. |
| [22] | Mueller I, Ehlert K, Endres S, et al. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO[J]. Mabs, 2018, 10(1): 55-61. |
| [23] | Lode HN. Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial[J/OL]. J Clin Oncol, 37, 2019 (suppl): abstr 10014. [2021-12-07]. https://meetings.asco.org/abstracts-presentations/170960. |
| [24] | Garaventa A, Parodi S, De Bernardi B, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry[J]. Eur J Cancer, 2009, 45(16): 2835-2842. |
| [25] | European Medicines Agency. Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)[EB/OL]. [2021-12-07]. https://www.ema.europa.eu/en/documents/product-information/qarziba-epar-product-information_en-0.pdf |
| [26] | 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)肿瘤放化疗相关中性粒细胞减少症规范化管理指南(2021)[J]. 临床肿瘤学杂志, 2021, 26(7): 638-648. |
| [27] | Barone G, Barry A, Bautista F, et al. Managing adverse events associated with dinutuximab beta treatment in patients with high-risk neuroblastoma: practical guidance[J]. Paediatr Drugs, 2021, 23(6): 537-548. |
| [28] | Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management[J]. Kidney Int, 2017, 92(1): 37-46. |
/
| 〈 |
|
〉 |
沪公网安备 31011002000392号
